ORLANDO — Initiation of biologic treatment for asthma is low despite availability, and adherence is low as well despite its association with good outcomes, according to data presented at the American Thoracic Society Annual Meeting. These gaps indicate opportunities for improving interventions, Justin Kwiatek, PharmD, senior director and U.S. medical affairs lead of respiratory biologics at